"I don't understand how Kelly Martin could be so bullish on bapineuzumab based on this data. Did he mislead us all?"Kelly Martin, Elan's CEO, has a BIG credibility problem with Wall Street. Without naming names, let's just say that I saw a couple of Elan's largest institutional shareholders at the ICAD conference Tuesday night, and they looked like they wanted to take Martin into an alley and, well, you get the idea. In an interview with CNBC Wednesday morning, Martin tried to blame Elan's selloff on too-high expectations and investors who want simple answers to complex questions. That's laughable. It was Martin, himself, who set those high expectations for bapineuzumab, and the data aren't difficult at all to understand. And it's Martin who fostered an arrogant, insular culture at Elan where friends were rewarded and anyone who dared question the company was frozen out. Now he wants to blame investors for the bapineuzumab fiasco? How lame. And now, Martin has an even bigger problem on his hands because few investors will give him the benefit of the doubt when he tries to soothe investor nerves about Tysabri.
Feuerstein's Biotech-Stock Mailbag: Elan
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.